InvestorsHub Logo

BonelessCat

10/23/14 12:25 PM

#74626 RE: TOB #74575

The bottom line: Based upon the data, Cellceutix has decided that a pivotal Phase 3 trial in 2015 will be for a single-dose of Brilacidin for ABSSSI.

loanranger

10/25/14 4:17 AM

#75252 RE: TOB #74575

Can I trouble you to explain, please?

Given:
"The primary endpoint was clinical success in the intent-to-treat population, defined as reduction of at least 20% in area of ABSSSI lesion, relative to baseline, when observed 48-72 hours after the first dose of study drug"
"All three Brilacidin treatment arms (two single-dose regimens and one three-day dose regimen) reached the primary endpoint"
"the clinical success rate for each dosing regimen statistically comparable to the clinical success rate of the FDA-approved seven-day dosing regimen of daptomycin"

If the clinical success (20% reduction in lesion area) at the endpoint of the Brilacidin treatment was measured at 48-72 hours after the first dose (at which point dosing would be at least 2/3 complete if not 1-2 days past completion), how can relative success be compared to the daptomycin regimen which, after 48-72 hours after the first dose, would only be 2/7 or 3/7 complete?

Thanks.

faxedreceipts

10/26/14 12:02 AM

#75367 RE: TOB #74575

Are there plans for the data to be submitted to a peer reviewed journal or have they already?

youssef

01/12/15 10:28 PM

#86398 RE: TOB #74575

Thank you everyone for the update , this is a great board and we are lucky to be a shareholders .

youssef

02/09/15 8:47 PM

#91021 RE: TOB #74575

I am confident with ctix and the management team , sa article is a waste , thanks Karin for your interview , patient will pay I invested in HGSI and went from 57 cents to over $30 the company get sold . This is a great board , thank you all

Ultimate01

04/21/15 5:40 PM

#98648 RE: TOB #74575

Loanranger, I comment with the utmost respect.

I just want to add that researchers and physicians/scientists often dabble in many things and sometimes those things may be or look uncomfortable from a purely financial prospective. A bit of latitude isn't too much to ask if you want the best, they must be vetted.

GO CTIX!

youssef

06/22/15 7:10 PM

#109093 RE: TOB #74575

Unfortunately no drug cancer could save my sister she passed last night in peace , my cousin son is a cancer doctor in USA and he worked before on imbuvica trial for pcyc and I talked to him about ctix and his answer was if the result showing in ph1 show what dr menon believe the result will be , ctix will be the mos valuable company , I am not here to bump , I own 50000 share and I m long and my co worker pick up 30000 at $2.49 , for all the peoples who are attacking Leo and management ,you are loosing the# cause of the drug what is saving life plus the money we all could make while we are helping saving life , follow the science instead the daily price and the up list without the science ctix is worst 0 even if the stock was trade in the Nasdaq . Good luck and go ctix the world need you